Incyte settles CMS rebate dispute, gains $246M Q2 benefit and improved Opzelura margins

Filed June 22, 2026 · Period ending June 22, 2026 · ~1 min read

Key Changes

• high

  CMS agreed not to treat Opzelura as a line extension of Jakafi for Medicaid rebate purposes, removing regulatory uncertainty over the drug's rebate obligations.

  Item 8.01 verify on EDGAR →
• high

  Incyte will record a one-time, non-cash benefit of approximately $246 million in Q2 2026 by reversing accruals for potential line extension rebate liabilities.

  Item 8.01 verify on EDGAR →
• high

  Opzelura's gross-to-net margin will improve going forward as Incyte stops accruing for line extension rebate liabilities, retaining more revenue per sale.

  Item 8.01 verify on EDGAR →